IL1B and neurodegenerative disease: Our results showing that appropriate doses of hNSC-EV treatment can modulate the release of proinflammatory cytokines TNF-α and IL-1β by activated human microglia suggests that such EVs could be used for treating neuroinflammation in neurodegenerative diseases.